Development of a New Carbohydrate Antibody to GalNac1-3Gal
Posted Aug 10 2009 5:00pm
Description of Invention: The present invention provides a monoclonal antibody that binds specifically to the antigen GalNAc1-3Gal present in human cancers, including squamous cell cancer, human cervical cancer, human esophageal cancer, human laryngeal cancer, and, human skin cancer. The antibody can be used to monitor expression of this carbohydrate for a variety of purposes. In immunohistochemical staining of tissues, the antibody stains a variety of carcinomas, with good staining of cervical, larynx, and skin squamous cell carcinomas. Positive antibody staining of cervical cancer tissue correlates with a good prognosis (increased 5 year survival rate) as such may be useful as a prognostic marker. NCI also has the parent cell line for production of the antibody and several other variant antibodies with similar reactivity.
Portfolios: Cancer Cancer - Diagnostics Cancer - Research Materials
For Additional Information Please Contact: Betty Tong Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-594-6565 Fax: 301-402-0220